Studies on MORA-therapy
Studies used in the following indication - or reference listing to prove an indication complies with at least two points of the following admission criteria:
- There is at least one positive study higher than the AHA compliant level 3 available.
- At least one study has been published in a recognised peer-review journal.
- The positive study result has been reproduced at least once by other independent authors.
Human studies
Human studies
Reference
Nienhaus (1999):
retrospective, uncontrolled case series in bei psychosomatic problems (including functional gastro-intestinal disorders), conducted with MORA-Super device MORA-Super-Gerät, practical trial
AHA evidence level : level 5
Nienhaus (2003):
controlled clinical study with clinical test plan, full documentation and case reports (sponsor: MedTronik GmbH), conducted with MORA-Super device, clinical trial.
published: Nienhaus und Galle 2006, Medline, peer-reviewed
AHA evidence level : level 2
Morell (1988):
prospective, non-comparative clinical application study, conducted with MORA-Super device, clinical trial
AHA evidence level : level 5
Schumacher (1994, 1998):
prospective, non-comparative application study, conducted with MORA-III device, clinical trial
AHA evidence level: level 5
Hennecke (1994):
retrospective, non-comparative, clinical application study, conducted with BICOM-device, clinical trial
AHA evidence level: level 5
Chervinskaya et al. (1997):
controlled clinical study (initiated by Med-Tronik GmbH), conducted with MORA-Super device (University St. Petersburg and Clinical-scientific centre St. Petersburg)
AHA evidence level : level 2-3
Kofler et al. (1996):
controlled clinical study – Medline, peer-reviewed (see additional sceptical comment on the interpretation of the results in Galle literature (2002)), conducted with MORA-Super device (University-Derma-clinic Innsbruck)
AHA evidence level: level 3
Schöni et al. (1997):
controlled clinical study – Medline, peer-reviewed, conducted with BICOM-device (Alpine children's hospital, Davos)
AHA eveidence level: level 1
Gogoleva (2001):
controlled clinical study – Med-line, peer-reviewed, conducted with IMEDIS-device (Institute for policlinical therapy, State Medical Academy, Orenburg)
AHA evidence level: level 3
Maiko and Gogoleva (2000):
controlled clinical study – Medline, peer-reviewed, conducted with IMEDIS-devicet (Institute for policlinical therapy, State Medical Academy, Orenburg)
AHA eveidence level: level 2
Islamov et al. (2002):
controlled clinical study – Medline, peer-reviewed, conducted with IMEDIS-device (Institute for theoretical and experimental Biophysics and Institute for Rheumatology, Russian Academy of Sciences)
AHA evidence level: level 3
Islamov et al. (1999): controlled clinical study – Medline, peer-reviewed, conducted with IMEDIS-device (Institute for theoretical and experimental Biophysics and Institute for Rheumatology, Russian Academy of sciences)
AHA evidence level: level 3
Schuller (2006):
partly controlled study with clinical test plan and all case reports (partly sponsored: MedTronik GMBH), conducted with MORA-Super device, clinical trial.
Published: Schuller and Galle 2007, Medline, peer-reviewed
AHA evidence level: level 3
Saweljew et al. (2001):
controlled clinical study, conducted with IMEDIS device (Pedeatric Iinstitute, Moskau)
AHA evidence level: level 2
Trofimov et al. (1997):
kcontrolled clinical study (initiated by MedTronik GmbH), conducted with MORA-Super device (University St. Petersburg and Clinical-scientific centre St. Petersburg)
AHA evidence level: level 3